Enantiomerically Pure CNS Compounds for Multi-Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for CNS diseases and disorders are not effective in addressing the needs of patients with depression, schizophrenia, and aggressive behavior in Alzheimer's disease.
Innovation Solution
Development of specific compounds, such as those of Formula I, II, III, IV, IVf, and IVl, which are enantiomerically pure and administered in a pharmaceutical formulation to treat CNS diseases and disorders, including depression, schizophrenia, and aggressive behavior in Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for CNS diseases, then current standard care is provided, but effectiveness is insufficient for depression, schizophrenia, and aggressive behavior in Alzheimer's disease
Solution Approach 1:
The patent applies universality by designing a single molecular framework (Formula I compounds with specific substituents R1-R7) that can treat multiple different CNS conditions including depression, schizophrenia, and aggressive behavior in Alzheimer's disease. The general structure with variable substituents allows one compound class to address diverse neurological disorders through modulation of different receptor systems.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying chemical parameters (substituents R1-R7, their positions, and configurations) to optimize the compound's interaction with different CNS target receptors. By changing molecular parameters such as substituent types and spatial arrangements, the same base structure can achieve different therapeutic effects for different conditions.
2Reliability
If enantiomerically pure compounds are synthesized, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies asymmetry by focusing on enantiomerically pure compounds where molecular chirality is critical for therapeutic efficacy. The specific stereochemical configuration at chiral centers (indicated by (R)- or (S)- prefixes in the compound names) is maintained to ensure consistent biological activity and reduce side effects, accepting the increased synthesis complexity as necessary for achieving the desired therapeutic reliability.
Data Source
AI summary
Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.